This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A New Phase in the Epidemic?

Roger J. Pomerantz, MD

JAMA. 1999;282:1177-1179.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The human immunodeficiency virus type 1 (HIV-1) epidemic, like the virus itself, continues to evolve. Over the last several years, the development of combination antiretroviral chemotherapy, able to suppress plasma virus to undetectable levels in many infected individuals, has led to a profound change in the epidemic, at least in the developed world. Both mortality and morbidity of HIV-1–infected individuals have been decreasing secondary to these combinations of antiretroviral agents, referred to as highly active antiretroviral therapy (HAART).^1-3

Nevertheless, during this evolution of the epidemic, viral resistance to all categories of approved antiretroviral agents has continued to develop and has confounded the successful treatment of many patients with HIV-1 infection.^4-10 Secondary development of resistance, after transmission to and dissemination of infection in HIV-1–seropositive individuals, can occur because of a number of factors.^4-7 These generally can be categorized into 2 major groups, patient noncompliance and nonsuppressive antiviral . . . [Full Text of this Article]

Author Affiliation: Departments of Medicine, Biochemistry, and Molecular Pharmacology, Division of Infectious Diseases, Center for Human Virology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

HIV-1 Drug Resistance in Newly Infected Individuals
Daniel Boden, Arlene Hurley, Linqi Zhang, Yunzhen Cao, Yong Guo, Elizabeth Jones, John Tsay, James Ip, Charles Farthing, Kay Limoli, Neil Parkin, and Martin Markowitz
JAMA. 1999;282(12):1135-1141.
ABSTRACT | FULL TEXT  

Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection
Susan J. Little, Eric S. Daar, Richard T. D'Aquila, Philip H. Keiser, Elizabeth Connick, Jeannette M. Whitcomb, Nicholas S. Hellmann, Christos J. Petropoulos, Lorraine Sutton, Jacqui A. Pitt, Eric S. Rosenberg, Richard A. Koup, Bruce D. Walker, and Douglas D. Richman
JAMA. 1999;282(12):1142-1149.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Changes in Sexual Behavior Among HIV-Infected Women After Initiation of HAART
Wilson et al.
AJPH 2004;94:1141-1146.
ABSTRACT | FULL TEXT  

Mother to Child Transmission of HIV
Newberry and Kelsey
Journal of Pharmacy Practice 2003;16:182-190.
ABSTRACT  

Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
Bahr et al.
J Antimicrob Chemother 2003;51:1377-1388.
ABSTRACT | FULL TEXT  

A Double-Blind, Adjuvant-Controlled Trial of Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Monotherapy in Asymptomatic, HIV-1-Infected Thai Subjects with CD4-Cell Counts of >300
Churdboonchart et al.
CVI 2000;7:728-733.
ABSTRACT | FULL TEXT  

The Case for More Cautious, Patient-Focused Antiretroviral Therapy
Henry
ANN INTERN MED 2000;132:306-311.
ABSTRACT | FULL TEXT  

Drug-Resistant HIV May Cause New Infections
Journal Watch Dermatology 1999;1999:15-15.
FULL TEXT  

Drug Resistance in Newly Infected Patients
AIDS Clin Care 1999;1999:3-3.
FULL TEXT  

Drug-Resistant HIV May Cause New Infections
JWatch General 1999;1999:1-1.
FULL TEXT